| Literature DB >> 27151424 |
Yu Togashi1, Jun Shirakawa1, Tomoko Okuyama1, Shunsuke Yamazaki1, Mayu Kyohara1, Ayumi Miyazawa1, Takafumi Suzuki1, Mari Hamada1, Yasuo Terauchi1.
Abstract
Glucometers are also widely used in diabetes research conducted using animal models. However, the appropriateness of measuring blood glucose levels using glucometers in animal models remains unclear. In this study, we evaluated the consistency between the blood glucose levels measured by 11 models of glucometers and plasma glucose levels measured by a laboratory biochemical test in blood samples collected by retro-orbital sinus puncture or tail-tip amputation. In both blood samples obtained by retro-orbital sinus puncture and those obtained by tail-tip amputation, 10 of the 11 models of glucometers yielded higher glucose values, while 1 yielded lower glucose values, than the plasma glucose values yielded by the laboratory test, the differences being in direct proportion to the plasma glucose values. Most glucometers recorded higher blood glucose levels after glucose loading and lower blood glucose levels after insulin loading in retro-orbital sinus blood as compared to tail vein blood. Our data suggest that the blood glucose levels measured by glucometers in mice tended to be higher than the plasma glucose levels yielded by the biochemical test under the hyperglycemic state, and that differences in the measured levels were observed according to the blood collection method depending on the glycemia status.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27151424 PMCID: PMC4858715 DOI: 10.1038/srep25465
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Comparison of the glucose concentrations measured by the glucometers (No. 1–11) and the plasma glucose concentrations measured by a laboratory method in blood samples obtained by retro-orbital puncture. Scatter plot (left) and Bland-Altman plot (right) of measurements by each glucometer (No. 1–11) and plasma glucose levels measured in the laboratory by the mutarotase GOD method (No. 12) in retro-orbital venous blood samples (N = 58). Solid lines in the scatter plots (left) represent lines of equivalence. Solid line in the Bland-Altman plot (right) represents estimated conditional mean values for glucometer coefficients derived by linear regression. Solid circles indicate samples within the measurement limits of the glucometer. Open angles indicate samples showing values over the limit of detection of the glucometers. The p value for the slope is indicated in the Bland-Altman plot.
Figure 2Comparison of the glucose concentrations measured by the glucometers (No. 1–11) and the plasma glucose concentrations measured by a laboratory method in blood samples obtained by tail-tip amputation. Scatter plot (left) and Bland-Altman plot (right) of measurements by each glucometer (No. 1–11) and plasma glucose levels measured in the laboratory by the mutarotase GOD method (No. 12) in tail-tip blood samples (N = 40). Solid lines in the scatter plots (left) represent lines of equivalence. Solid line in the Bland-Altman plot (right) represents estimated conditional mean values for glucometer coefficients derived by linear regression. Solid circles indicate samples within the measurement limits of the glucometer. Open angles indicate samples showing values over the limit of detection of the glucometers. The p value for the slope is indicated in the Bland-Altman plot.
The difference between glucometer (No. 1–11) and laboratory method (No. 12) in retro-orbital blood glucose levels.
| Glucose range in No. 12 (mg/dL) | ||||||||
|---|---|---|---|---|---|---|---|---|
| 0–99 | 100–199 | 200–299 | 300– | |||||
| (mg/dL) | (%) | (mg/dL) | (%) | (mg/dL) | (%) | (mg/dL) | (%) | |
| Glucose value (No. 1–12) (mg/dL) | 20.6 ± 3.4 | 34.7 ± 6.6 | 43.5 ± 8.8 | 30.5 ± 5.7 | 53.8 ± 11.1 | 20.1 ± 4.0 | 65.1 ± 13.6 | 16.5 ± 3.3 |
| Glucose value (No. 2–12) (mg/dL) | 30.1 ± 2.6 | 47.0 ± 5.3 | 42.9 ± 8.0 | 30.2 ± 5.2 | 60.5 ± 14.0 | 22.9 ± 4.9 | 101.6 ± 21.9 | 25.2 ± 5.3 |
| Glucose value (No. 3–12) (mg/dL) | − 9.2 ± 3.3 | − 10.3 ± 4.5 | 10.8 ± 8.3 | 7.4 ± 5.4 | 8.5 ± 9.1 | 3.0 ± 3.3 | 37.6 ± 19.1 | 8.5 ± 4.5 |
| Glucose value (No. 4–12) (mg/dL) | − 7.7 ± 3.5 | 8.1 ± 5.0 | 10.8 ± 8.3 | 7.5 ± 5.4 | 8.3 ± 7.6 | 2.9 ± 2.8 | 35.1 ± 20.1 | 7.7 ± 4.8 |
| Glucose value (No. 5–12) (mg/dL) | 6.1 ± 3.2 | 11.9 ± 5.0 | 30.7 ± 8.7 | 21.5 ± 5.6 | 38.0 ± 9.7 | 14.2 ± 3.5 | 26.2 ± 10.9 | 6.8 ± 2.8 |
| Glucose value (No. 6–12) (mg/dL) | − 8.5 ± 3.9 | − 9.5 ± 5.3 | − 11.3 ± 7.1 | − 7.3 ± 4.5 | − 26.6 ± 9.3 | − 10.0 ± 3.3 | − 52.4 ± 14.2 | − 13.6 ± 3.7 |
| Glucose value (No. 7–12) (mg/dL) | − 0.5 ± 3.1 | 2.3 ± 4.6 | 16.3 ± 8.9 | 11.3 ± 5.7 | 28.3 ± 11.0 | 10.5 ± 4.1 | 53.1 ± 19.7 | 12.8 ± 4.8 |
| Glucose value (No. 8–12) (mg/dL) | 13.0 ± 3.4 | 22.3 ± 5.5 | 29.0 ± 8.6 | 20.2 ± 5.6 | 37.7 ± 9.8 | 14.4 ± 3.6 | 48.0 ± 14.1 | 12.0 ± 3.4 |
| Glucose value (No. 9–12) (mg/dL) | 3.6 ± 3.2 | 8.7 ± 5.0 | 18.2 ± 8.8 | 13.1 ± 5.7 | 22.8 ± 10.2 | 8.7 ± 3.7 | 39.3 ± 13.7 | 9.7 ± 3.4 |
| Glucose value (No. 10–12) (mg/dL) | − 1.1 ± 3.2 | 8.7 ± 4.6 | 23.8 ± 9.5 | 16.2 ± 6.0 | 42.8 ± 10.8 | 16.3 ± 3.9 | 64.2 ± 18.5 | 16.0 ± 4.7 |
| Glucose value (No. 11–12) (mg/dL) | 27.2 ± 3.5 | 44.1 ± 6.6 | 72.3 ± 11.3 | 49.7 ± 7.4 | 109.6 ± 13.9 | 41.3 ± 4.8 | 130.0 ± 14.0 | 33.5 ± 3.7 |
values are mean ± SE. Sample number at − 100 mg/dL, 100–200 mg/dL, 200–300 mg/dL and 300– mg/dL glucose range is 29, 33, 13 and 10 respectively.
The difference between glucometer (No. 1–11) and laboratory method (No. 12) in tail-tip blood glucose levels.
| Glucose range in No. 12 (mg/dL) | ||||||||
|---|---|---|---|---|---|---|---|---|
| –99 | 100–199 | 200–299 | 300– | |||||
| (mg/dL) | (%) | (mg/dL) | (%) | (mg/dL) | (%) | (mg/dL) | (%) | |
| Glucose value (No. 1–12) (mg/dL) | 13.1 ± 3.7 | 16.1 ± 4.3 | 18.2 ± 4.7 | 11.9 ± 3.4 | 39.0 ± 20.1 | 16.8 ± 8.2 | 91.1 ± 32.2 | 25.6 ± 9.7 |
| Glucose value (No. 2–12) (mg/dL) | 31.4 ± 3.6 | 37.3 ± 4.7 | 23.8 ± 3.6 | 15.9 ± 2.4 | 47.4 ± 21.3 | 20.8 ± 8.8 | 144.4 ± 40.8 | 39.1 ± 12.0 |
| Glucose value (No. 3–12) (mg/dL) | − 11.9 ± 2.6 | − 13.5 ± 2.4 | − 3.2 ± 4.8 | − 3.0 ± 3.3 | 13.5 ± 14.5 | 6.2 ± 5.9 | 57.4 ± 36.3 | 15.9 ± 10.8 |
| Glucose value (No. 4–12) (mg/dL) | − 16.9 ± 5.4 | − 19.3 ± 5.4 | 1.9 ± 3.9 | 0.3 ± 2.8 | 13.0 ± 12.4 | 5.8 ± 5.0 | 52.7 ± 35.7 | 14.7 ± 10.6 |
| Glucose value (No. 5–12) (mg/dL) | 5.4 ± 4.6 | 7.9 ± 5.0 | 20.7 ± 5.2 | 13.2 ± 3.4 | 48.4 ± 15.1 | 20.8 ± 6.4 | 72.1 ± 31.6 | 20.8 ± 9.2 |
| Glucose value (No. 6–12) (mg/dL) | − 17.9 ± 4.6 | − 20.6 ± 4.0 | − 27.7 ± 4.1 | − 18.8 ± 2.8 | − 29.6 ± 29.6 | − 11.9 ± 6.3 | − 27.4 ± 27.0 | − 7.1 ± 7.8 |
| Glucose value (No. 7–12) (mg/dL) | − 5.7 ± 5.6 | − 7.0 ± 6.6 | − 6.2 ± 3.6 | − 5.1 ± 2.5 | 15.9 ± 20.6 | 7.6 ± 8.3 | 74.7 ± 38.5 | 19.5 ± 11.7 |
| Glucose value (No. 8–12) (mg/dL) | 10.1 ± 4.3 | 12.5 ± 4.7 | 15.9 ± 4.5 | 10.1 ± 3.0 | 36.5 ± 17.9 | 15.9 ± 7.3 | 74.4 ± 35.6 | 20.8 ± 10.6 |
| Glucose value (No. 9–12) (mg/dL) | − 1.4 ± 3.7 | − 1.2 ± 3.8 | 4.7 ± 4.0 | 2.7 ± 2.8 | 11.9 ± 16.3 | 5.7 ± 6.5 | 74.7 ± 41.3 | 19.9 ± 11.9 |
| Glucose value (No. 10–12) (mg/dL) | − 9.1 ± 3.5 | − 10.0 ± 3.4 | − 1.6 ± 4.1 | − 1.9 ± 2.9 | 20.7 ± 18.7 | 8.9 ± 7.6 | 70.4 ± 38.5 | 19.2 ± 11.5 |
| Glucose value (No. 11–12) (mg/dL) | 3.8 ± 4.0 | 4.9 ± 4.3 | 26.8 ± 6.9 | 17.4 ± 4.7 | 79.4 ± 19.9 | 33.1 ± 8.2 | 20.9 ± 73.3 | 2.8 ± 21.4 |
values are mean ± SE. Sample number at − 100 mg/dL, 100–200 mg/dL, 200–300 mg/dL and 300– mg/dL glucose range is 6, 18, 10 and 6 respectively.
Figure 3Effect of the method used for the blood collection: retro-orbital vessel puncture vs. tail-tip amputation. Plasma glucose levels were measured in the laboratory by the mutarotase GOD method (No. 12), and blood glucose levels were measured by each glucometer (No. 1–11). (a) Sampling in the random-fed status (N = 18). (b) Sampling conducted 15 min after oral glucose loading (N = 10). (c) Sampling conducted 30 min after intraperitoneal insulin loading (N = 8). *P < 0.05. **P < 0.01. Values are the means ± SE. Black bars, retro-orbital vessels, White bars, tail-tip.
Characteristics of self-monitoring glucometers (No. 1–11) and a laboratory method (No. 12).
| No | Product | Measurement principle | Testing time (second) | Sample size (μL) | Sample type | Measurement range (mg/dL) | Calibration |
|---|---|---|---|---|---|---|---|
| 1 | ACCU-CHECK Compact Plus® | Mut. Q-GDH colorimetric method | 5 | 1.5 | Whole blood | 10–600 | Control solution |
| 2 | Medisafe mini® | GOD-POD colorimetric method | 10 | 1.2 | Whole blood | 20–600 | Automatic |
| 3 | Glutest neo alfa® | FAD-GDH electrode method | 5.5 | 0.6 | Whole blood | 10–600 | Automatic |
| 4 | Glutest neo super® | FAD-GDH electrode method | 5.5 | 0.6 | Whole blood | 10–600 | Automatic |
| 5 | Glutest mint® | FAD-GDH electrode method | 7 | 0.6 | Whole blood Plasma | 10–1000 10–600 | Control solution |
| 6 | Freestyle Freedom Lite® | FAD-GDH electrode method | 4 | 0.3 | Whole blood | 20–500 | Control solution |
| 7 | LIFE CHECK® | GDH electrode method | 5 | 1 | Whole blood | 20–900 | Control solution |
| 8 | ACCU-CHECK Aviva Nano® | Mut. Q-GDH electrode method | 5 | 0.6 | Whole blood | 10–600 | Code key |
| 9 | Stat Strip Xpress® | GOD electrode method | 6 | 1.2 | Whole blood | 20–600 | Control solution |
| 10 | ONETOUCH Ultra Vue® | GOD electrode method | 5 | 1 | Whole blood | 20–600 | Control solution |
| 11 | CareFast C® | GOD electrode method | 5 | 0.5 | Whole blood | 20–600 | Control solution |
| 12 | LabAssayTM Glucose | Mutarotase-GOD method | 300 | 2 | Plasma Serum | 0–500 |